News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Akebia (AKBA) Announces Third Quarter 2016 Financial Results



11/10/2016 3:11:32 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2016.

“This quarter, we continued to advance our Phase 3 program for vadadustat with the initiation of INNO2VATE for dialysis-dependent patients with anemia related to chronic kidney disease, our second potential indication. In addition, the Independent Data Monitoring Committee for the PRO2TECT program for non-dialysis patients met for the first time and recommended continuing the program without modification,” said John P. Butler, President and Chief Executive Officer of Akebia. “Clinical results of vadadustat were published for the first time, and multiple publications highlighted the clinical need for new treatment options such as vadadustat. Importantly, we added significant depth to our management team to not only drive our Phase 3 program, but also to focus on building our pipeline. Our pursuit of a geographic collaboration for vadadustat remains a core focus, with the goal of providing a strong commercial partner and the resources to finance the balance of our Phase 3 program.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES